SARS-Coronavirus Nucleocapsid Protein (SARS-CoV N) antibody

Catalog No. ABIN6952544

Product Details

Key Features:

• Detection of SARS-CoV-2 with variety of different immunoassays, i.e. ELISA, Lateral Flow, as validated by numerous publications (see below).
• Nucleocapsid antibody used for diagnostic Covid19 testing as well as for drug discovery.
• Developed and manufactured in the U.S.

Target: SARS-Coronavirus Nucleocapsid Protein (SARS-CoV N)

Reactivity: SARS Coronavirus (SARS-CoV), SARS Coronavirus-2 (SARS-CoV-2)

Host: Rabbit

Clonality: Polyclonal

Conjugate: Un-conjugated

Application: ELISA, Western Blotting (WB), Immunofluorescence (IF), Flow Cytometry (FACS), Fluorescence in situ hybridization (FISH), Immunohistochemistry (IHC)

Specificity: Detects the Nucleocapsid (N), Omicron, and BA.2 sub-variant.

Cross-Reactivity (Details): BLAST analysis was used to suggest reactivity with related Coronavirus proteins. Cross reactivity with homologues from other sources has not been determined.

Predicted Reactivity: Predicted reactivity based on immunogen sequence: SARS-CoV2 Nucleocapsid protein: (homology 90%)

Purification: This protein A purified antibody is directed against SARS Coronavirus Nucleocapsid (N) protein. The product was purified from monospecific antiserum by protein A affinity purification.

Immunogen: This protein A purified antibody was prepared from whole rabbit serum produced by repeated immunizations with a purified recombinant protein corresponding to full length SARS Coronavirus Nucleocapsid protein. Lifesensors Inc. prepared the Nucleocapsid protein as follows: SUMO-Nucleocapsid fusion was expressed in E.coli in LB medium and purified using using Ni-NTA resin (Qiagen) affinity chromatography. After the fusion was cleaved by the SUMO Protease (LifeSensors), the SUMO tag and protease were subtracted from the nucleocapsid using MAC and the nucleocapsid was finally purified using Cation Exchange Chromatography with the Macro-Prep High S resin (BioRad) and size exclusion chromatography.
Immunogentype:Recombinant

Isotype: IgG

Application Details

Application Notes: ELISA : 1:10,000 - 1:50,000
IF Microscopy : User Optimized
Flow Cytometry : User Optimized
Western Blot : 1:2,000 - 1:10,000
Immunohistochemistry: 1:100-1:6000

This protein A purified antibody has been tested for use in ELISA, western blot, Immunohistochemistry, Immunofluorescence, and lateral flow. Specific conditions for reactivity should be optimized by the end user. Expect a band approximately 46 kDa in size corresponding to SARS Nucleocapsid (N) protein by western blotting in the appropriate cell lysate or extract. ELISA and lateral flow format has been used to detect virus in extracts from nasal and throat swabs and saliva. IF has been used to determine the presence or absence of virus entering cells especially when anti-viral drugs are applied. IHC studies have been performed on biopsies, included retrospective studies on cadaver tissues after formalin fixation and paraffin embedding, detecting the coronavirus in lung, liver, bile duct, and placenta tissue. Yet other studies have shown this antibody has the ability to neutralize the virus and thereby protect cells from the uptake of live virus. Others have demonstrated the utility of the antibody in flow cytometry studies.

Comment:

Expect a band approximately 46 kDa in size corresponding to SARS Nucleocapsid (N) protein by western blotting in the appropriate cell lysate or extract.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Restore with deionized water (or equivalent)

Concentration: 5.3 mg/mL

Buffer:

Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2

0.01 % (w/v) Sodium Azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C

Storage Comment: Store vial at 4° C prior to restoration. For extended storage aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.

References

Pedersen, Koumakpayi, Babuadze, Baz, Ndiaye, Faye, Diagne, Dia, Naghibosadat, McGeer, Muberaka, Moukandja, Ndidi, Tauil, Lekana-Douki, Loucoubar, Faye, Sall, Magalhães, Weis, Kozak, Kobinger et al.: "Cross-reactive immunity against SARS-CoV-2 N protein in Central and West Africa precedes the COVID-19 pandemic. ..." in: Scientific reports, Vol. 12, Issue 1, pp. 12962, (2022) (PubMed).

Fattori, Cribier, Chenard, Mitcov, Mayeur, Weingertner: "Cutaneous manifestations in patients with coronavirus disease 2019: clinical and histological findings." in: Human pathology, Vol. 107, pp. 39-45, (2021) (PubMed).

Cervia, Nilsson, Zurbuchen, Valaperti, Schreiner, Wolfensberger, Raeber, Adamo, Weigang, Emmenegger, Hasler, Bosshard, De Cecco, Bächli, Rudiger, Stüssi-Helbling, Huber, Zinkernagel, Schaer, Aguzzi et al.: "Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. ..." in: The Journal of allergy and clinical immunology, Vol. 147, Issue 2, pp. 545-557.e9, (2021) (PubMed).

Zhu, Feng, Hu, Wang, Yu, Zhu, Xu, Cai, Sun, Han, Ye, Qu, Ding, Huang, Chen, Xu, Xie, Cai, Yuan, Zhang: "A genome-wide CRISPR screen identifies host factors that regulate SARS-CoV-2 entry." in: Nature communications, Vol. 12, Issue 1, pp. 961, (2021) (PubMed).

Hekman, Hume, Goel, Abo, Huang, Blum, Werder, Suder, Paul, Phanse, Youssef, Alysandratos, Padhorny, Ojha, Mora-Martin, Kretov, Ash, Verma, Zhao, Patten, Villacorta-Martin, Bolzan, Perea-Resa, Bullitt et al.: "Actionable Cytopathogenic Host Responses of Human Alveolar Type 2 Cells to SARS-CoV-2. ..." in: Molecular cell, Vol. 80, Issue 6, pp. 1104-1122.e9, (2021) (PubMed).

Thao, Labroussaa, Ebert, Vkovski, Stalder, Portmann, Kelly, Steiner, Holwerda, Kratzel, Gultom, Schmied, Laloli, Hüsser, Wider, Pfaender, Hirt, Cippà, Crespo-Pomar, Schröder, Muth, Niemeyer, Corman et al.: "Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform. ..." in: Nature, (2020) (PubMed).

Huang, Hume, Abo, Werder, Villacorta-Martin, Alysandratos, Beermann, Simone-Roach, Lindstrom-Vautrin, Olejnik, Suder, Bullitt, Hinds, Sharma, Bosmann, Wang, Hawkins, Burks, Saeed, Wilson, Mühlberger et al.: "SARS-CoV-2 Infection of Pluripotent Stem Cell-Derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response. ..." in: Cell stem cell, Vol. 27, Issue 6, pp. 962-973.e7, (2020) (PubMed).

Nienhold, Ciani, Koelzer, Tzankov, Haslbauer, Menter, Schwab, Henkel, Frank, Zsikla, Willi, Kempf, Hoyler, Barbareschi, Moch, Tolnay, Cathomas, Demichelis, Junt, Mertz: "Two distinct immunopathological profiles in autopsy lungs of COVID-19." in: Nature communications, Vol. 11, Issue 1, pp. 5086, (2020) (PubMed).

Holwerda, Vkovski, Wider, Thiel, Dijkman: "Identification of an Antiviral Compound from the Pandemic Response Box that Efficiently Inhibits SARS-CoV-2 Infection In Vitro." in: Microorganisms, Vol. 8, Issue 12, (2020) (PubMed).

Bouhaddou, Memon, Meyer, White, Rezelj, Correa Marrero, Polacco, Melnyk, Ulferts, Kaake, Batra, Richards, Stevenson, Gordon, Rojc, Obernier, Fabius, Soucheray, Miorin, Moreno, Koh, Tran, Hardy et al.: "The Global Phosphorylation Landscape of SARS-CoV-2 Infection. ..." in: Cell, Vol. 182, Issue 3, pp. 685-712.e19, (2020) (PubMed).

Grant, Anderson, Williford, Alonzo, Glukhova, Boyle, Weigl, Nichols: "SARS-CoV-2 Coronavirus Nucleocapsid Antigen-Detecting Half-Strip Lateral Flow Assay Toward the Development of Point of Care Tests Using Commercially Available Reagents." in: Analytical chemistry, Vol. 92, Issue 16, pp. 11305-11309, (2020) (PubMed).

Sauvat, Ciccosanti, Colavita, Di Rienzo, Castilletti, Capobianchi, Kepp, Zitvogel, Fimia, Piacentini, Kroemer: "On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2." in: Cell death & disease, Vol. 11, Issue 8, pp. 656, (2020) (PubMed).

Yurkovetskiy, Wang, Pascal, Tomkins-Tinch, Nyalile, Wang, Baum, Diehl, Dauphin, Carbone, Veinotte, Egri, Schaffner, Lemieux, Munro, Rafique, Barve, Sabeti, Kyratsous, Dudkina, Shen, Luban: "Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant." in: Cell, Vol. 183, Issue 3, pp. 739-751.e8, (2020) (PubMed).

Target Details

Target: SARS-Coronavirus Nucleocapsid Protein (SARS-CoV N)

Alternative Name: Sars Nucleocapsid Protein (SARS-CoV N Products)

Synonyms: NC antibody, Protein N antibody, nucleocapsid protein antibody, N antibody

Target Type: Viral Protein

Background: The coronavirus nucleocapsid protein is the major structural component of virions that associates with genomic RNA to form a long, flexible, helical nucleocapsid. Sequence comparison of the N genes of five strains of the coronavirus mouse hepatitis virus suggests a three-domain structure for the nucleocapsid protein.
Synonyms: N antibody, N structural protein antibody, NC antibody, Nucleocapsid protein antibody, Nucleoprotein antibody, SARS coronavirus N protein antibody, SARS CoV antibody, SARSCoV antibody, Severe acute respiratory syndrome antibody

Gene ID: 1489678, 30173007

UniProt: P59595